Regulatory Compliance Associates (RCA), a Nelson Labs company, along with Sterigenics and Nelson Labs, part of Sotera Health, offer an integrated suite of services tailored for wearable and implantable connected medical devices. From concept to commercialization, they help navigate complex regulatory landscapes, ensuring quality, safety, and speed to market.
Why Choose Us?
- Expert Guidance: Advisory services covering design, regulatory strategy, software development (including SaMD), cybersecurity, and risk management.
- Advanced Testing: Material compatibility, biocompatibility, battery performance, microbial testing, and more.
- Sterilization Excellence: Full-spectrum sterilization technologies including Gamma, EO, E-Beam, X-Ray, and Nitrogen Dioxide, with global GMP-certified facilities.
- Global Reach: Serving over 5,000 customers across 62 facilities in 13 countries.
Integrated Ecosystem for Connected Care
RCA, Sterigenics, and Nelson Labs support the entire connected device lifecycle, ensuring seamless integration with electronic health records and AI-driven care platforms.
Learn how RCA, Sterigenics, and Nelson Labs can accelerate your connected medical device project with unmatched expertise and global capabilities.
In today’s connected healthcare landscape, cybersecurity is not just a technical requirement, it’s a strategic investment. For medical device manufacturers, early planning can significantly reduce cybersecurity costs while improving compliance, product safety, and time to market. In this blog, we explore how proactive cybersecurity planning can help companies avoid costly mistakes and meet evolving regulatory expectations in both the U.S. and EU.
1. Start Cybersecurity at the Concept Phase
Waiting until the end of development to address cybersecurity can lead to expensive redesigns and regulatory delays. By integrating cybersecurity from the concept phase, manufacturers can identify risks early and design secure systems from the ground up.
2. Build Threat Modeling into Your Design Process
Threat modeling helps identify potential vulnerabilities before they become embedded in the product. This proactive approach reduces the need for costly post-development fixes and supports FDA and EU compliance.
3. Develop a Comprehensive SBOM Early
A complete Software Bill of Materials (SBOM) is now a regulatory requirement. Creating it early ensures transparency, streamlines vulnerability management, and avoids last-minute compliance issues.
4. Align with Global Cybersecurity Standards
Following international standards like ISO/IEC 81001-5-1 and FDA premarket guidance from the start helps reduce rework and ensures smoother regulatory submissions across markets.
5. Collaborate with Cybersecurity Experts
Partnering with experienced cybersecurity consultants can help identify risks, implement best practices, and avoid costly missteps. Expert guidance ensures your team stays ahead of evolving regulations and industry expectations.
Partner with Regulatory Compliance Associates®
Early cybersecurity planning is not just cost-effective, it’s essential for regulatory success and patient safety. By embedding cybersecurity into every stage of product development, medical device manufacturers can reduce costs, accelerate time to market, and build more secure, compliant products.
Regulatory Compliance Associates® (RCA) helps medical device companies reduce cybersecurity costs through early planning, threat modeling, SBOM development, and global regulatory strategy. Contact RCA today to learn how our experts can support your secure product development journey.
Michelle Heiter, laboratory and quality control specialist, and Susan J. Schniepp, distinguished fellow, Regulatory Compliance Associates, a Nelson Labs Company, discuss how to effectively use contamination control strategies in your operations.
Key Takeaways
- A CCS is mandated by EU and US regulations and ICH guidelines to ensure product safety and compliance in pharmaceutical manufacturing.
- Key CCS elements include monitoring, validation, contamination controls, and fostering a quality culture through personnel management.
- Risk assessments identify and prioritize contamination risks, enabling targeted preventative measures and resource allocation.
- A robust CCS enhances product quality, patient safety, and regulatory compliance, fostering continuous improvement and company reputation
Q. What is a contamination control strategy (CCS) and how does it support sustainable compliance and continuous improvement?
A. A CCS is required in pharmaceutical manufacturing to ensure product safety, regulatory compliance, and efficient operations. The updated EudraLex, Volume 4, Annex 1 (1) mandates a CCS for sterile manufacturing in the European Union, aligning with similar FDA requirements (2, 3) in the United States, as well as International Council for Harmonisation (ICH) Q9 Quality Risk Management (4) and ICH Q10 Pharmaceutical Quality System (5) guidelines.
A review of FDA 483s and FDA Complete Response Letters (CRLs) highlights areas for improvement in pharmaceutical manufacturing. Citations have been issued for deficiencies related to microbial contamination, environmental monitoring, and aseptic practices. Addressing these observations is required for drug approvals and to strengthen a CCS.
A CCS is a holistic approach to minimizing contamination by evaluating good manufacturing practices (GMPs). A CCS provides a proactive method for identifying, controlling, and scientifically evaluating quality risks designed to reduce contamination and enhance product safety and quality.
Elements of a CCS include the following (6):
- Monitoring controls—personnel, in-process, materials, environmental, utilities, and pest controls
- Validation controls—qualification/requalification of personnel, process, analytical methods, facility, utilities, and equipment
- Contamination controls—personnel training, hygiene and gowning, process design, vendor material, consumable containers, equipment design, cleaning and sanitization
- Personnel awareness/quality culture
- Quality risk management and risk assessment identify potential contamination sources and assess their impact on product quality and safety
- Scientific and technical knowledge to prevent contamination
- Personnel management to empower personnel through training. Staff education, awareness, and skills play a crucial role in maintaining contamination control.
A strong CCS serves as an invaluable quality tool, ensuring regulatory compliance while safeguarding product quality, safety, and enhancing the company’s reputation. Let’s embrace its power!
Q. Why is a risk assessment required for a CCS?
A. Conducting a risk assessment is critical for a successful CCS. It helps to proactively identify contamination sources and their effects, enabling implementation of targeted preventative measures that safeguard both products and the well-being of patients.
A risk assessment is key to:
- Identify hazards and risks before they turn into real problems.
- Prioritize control measures based on the severity and likelihood of each risk to enable the allocation of resources to the areas vulnerable to contamination.
- Regulatory compliance and a commitment to product quality and safety are essential for meeting regulatory standards in our industry.
- Fostering continuous improvement by gathering insights, streamlining processes, and embracing innovative technologies. A proactive approach reduces risks and drives growth. This approach enables us to maintain control at every stage of the product lifecycle.
- Encouraging a culture of safety that involves cross-functional team members in the risk assessment process. This approach helps everyone understand and take responsibility for contamination control.
A robust CCS begins with a risk assessment. By proactively identifying and addressing contamination risks, we improve product quality, prioritize patient safety, and confidently meet regulatory standards.
References
- European Commission. EudraLex–Volume 4–Good Manufacturing Practice (GMP) Guidelines: Annex 1–Manufacture of Sterile Medicinal Products (2022 revision).
- FDA. Code of Federal Regulations Title 21, Parts 201 and 211. Current Good Manufacturing Practice for Drugs. 2023.
- Parenteral Drug Association. Technical Report No. 90: Contamination Control Strategy Development in Pharmaceutical Manufacturing (PDA, 2023).
- ICH. Q9 Quality Risk Management (ICH, 2005).
- ICH. Q10 Pharmaceutical Quality Systems (ICH, 2008).
- Chakraborty, S. and Baseman, H. Contamination Control Strategies: A Path for Quality and Safety. PDA.org, May 8, 2022, pda.org/pda-letter-portal/home/full-article/contamination-control-strategies-a-path-for-quality-safety (accessed Jul. 21, 2025).
Article details
Pharmaceutical Technology®
Vol. 49, No. 7
Page: 34
Citation
When referring to this article, please cite it as Heiter, M. and Schniepp, S. Effectively Using Contamination Control Strategies. Pharmaceutical Technology 2025 49 (7).
As the healthcare industry continues to embrace digital transformation, connected medical devices are becoming more common—and more vulnerable. From insulin pumps and pacemakers to remote monitoring systems and diagnostic tools, these devices are increasingly exposed to cyber threats that can compromise patient safety, data integrity, and regulatory compliance.
In this blog, we explore the top cybersecurity risks facing connected medical devices and share expert insights on how manufacturers can stay ahead of evolving threats and meet global regulatory expectations.
Listen to this podcast where we take a deeper dive into the Cybersecurity risks associated with Connected Medical Devices
Late Integration of Cybersecurity in Product Development
One of the most frequent mistakes medical device manufacturers make is waiting too long to address cybersecurity. Cybersecurity should be embedded early in the medical device development lifecycle, not added as an afterthought. Delayed integration can lead to vulnerabilities that are costly to fix and may result in regulatory delays or denials.
Tip: Begin threat modeling immediately after defining device features to ensure secure design specifications and reduce remediation costs.
Incomplete Software Bill of Materials (SBOM)
A comprehensive Software Bill of Materials (SBOM) is now a regulatory requirement in both the U.S. and EU. Many companies still submit SBOMs that lack depth, omitting nested components or failing to meet machine-readable format standards. This can lead to compliance issues and increased risk exposure.
Tip: Include all software layers—components of components—and ensure your SBOM is both human- and machine-readable.
Legacy Devices with Outdated Security
Legacy medical devices often lack modern cybersecurity features such as patching capabilities, logging, and threat detection. These devices pose a significant risk, especially when integrated into hospital networks.
Tip: Conduct a full cybersecurity assessment of legacy devices and plan for updates or redesigns that meet current FDA cybersecurity guidance and EU MDR requirements.
Lack of Threat Modeling and Vulnerability Management
Without proper threat modeling, manufacturers may overlook critical vulnerabilities. Additionally, failing to maintain a coordinated vulnerability disclosure program can result in non-compliance and reputational damage.
Tip: Implement a secure product development framework that includes threat modeling, penetration testing, and vulnerability traceability.
Overexposed Physical and Network Interfaces
Ports like USB, Bluetooth, and Wi-Fi can be exploited if not properly secured. Devices with exposed service ports or debug features are particularly vulnerable to unauthorized access.
Tip: Use physical controls (e.g., security screws, access doors) to limit exposure. Disable unnecessary ports and implement strong authentication protocols.
Misalignment with Global Regulatory Requirements
With evolving guidance from the FDA, EU MDR, UK MHRA, and the Cyber Resilience Act, companies must ensure their cybersecurity practices align across markets. Misalignment can lead to costly redesigns and delayed market access.
Tip: Stay informed on global cybersecurity regulations and work with experts who understand regional differences and harmonization efforts.
Final Thoughts
Cybersecurity in connected medical devices is no longer optional—it’s a regulatory and ethical imperative. By addressing these risks early and thoroughly, manufacturers can protect patients, ensure compliance, and maintain trust in their products.
Ready to Strengthen Your Cybersecurity Strategy?
Regulatory Compliance Associates® (RCA) specializes in helping medical device companies navigate the complex world of cybersecurity compliance, from SBOM development and threat modeling to FDA submissions and global market access. Contact RCA today to schedule a consultation with our cybersecurity experts and ensure your device is secure, compliant, and ready for market.